Zhaohui Zhang1, Yi Zhang1, Wei Wang2, Yunpeng Hua1, Linyun Liu1, Shunli Shen3, Baogang Peng4. 1. Department of Hepatic Surgery, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. 2. Department of Medical Ultrasonics, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. 3. Department of Hepatic Surgery, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. Electronic address: shunlishen@163.com. 4. Department of Hepatic Surgery, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. Electronic address: pengbaogang@medmail.com.cn.
Abstract
BACKGROUND: Recently, increasing studies have revealed the association of inflammatory parameters, such as preoperative platelet count, and the prognosis of hepatocellular carcinoma (HCC). However, the link between the platelet count and the prognosis of patients with HCC after hepatic resection is still controversial. METHODS: We searched PubMed, Web of Science, EMBASE, and CBM for relevant trials and analyzed outcomes with random-effects model. The hazard ratio (HR) and its 95% confidence interval (CI) were calculated. RESULTS: In total, 31 studies, including a total of 10,730 patients, met our criteria. The results showed that thrombocytopenia in HCC patients was associated with poor overall survival (HR = 1.47, 95% CI: 1.21-1.78), disease-free survival (HR = 1.36, 95% CI: 1.08-1.72), and a high risk of cancer recurrence (HR = 1.41, 95% CI: 1.22-1.62), but a low risk of extrahepatic metastasis (HR = 0.55, 95% CI: 0.47-0.63). CONCLUSIONS: The meta-analysis revealed that preoperative platelet count could act as a significant biomarker in the prognosis of HCC, especially a platelet count of <100 × 103/mm3. Additional high-quality trials are needed, considering the low-quality studies analyzed.
BACKGROUND: Recently, increasing studies have revealed the association of inflammatory parameters, such as preoperative platelet count, and the prognosis of hepatocellular carcinoma (HCC). However, the link between the platelet count and the prognosis of patients with HCC after hepatic resection is still controversial. METHODS: We searched PubMed, Web of Science, EMBASE, and CBM for relevant trials and analyzed outcomes with random-effects model. The hazard ratio (HR) and its 95% confidence interval (CI) were calculated. RESULTS: In total, 31 studies, including a total of 10,730 patients, met our criteria. The results showed that thrombocytopenia in HCC patients was associated with poor overall survival (HR = 1.47, 95% CI: 1.21-1.78), disease-free survival (HR = 1.36, 95% CI: 1.08-1.72), and a high risk of cancer recurrence (HR = 1.41, 95% CI: 1.22-1.62), but a low risk of extrahepatic metastasis (HR = 0.55, 95% CI: 0.47-0.63). CONCLUSIONS: The meta-analysis revealed that preoperative platelet count could act as a significant biomarker in the prognosis of HCC, especially a platelet count of <100 × 103/mm3. Additional high-quality trials are needed, considering the low-quality studies analyzed.
Authors: Bernhard Scheiner; Martha Kirstein; Sabine Popp; Florian Hucke; Simona Bota; Nataliya Rohr-Udilova; Thomas Reiberger; Christian Müller; Michael Trauner; Markus Peck-Radosavljevic; Arndt Vogel; Wolfgang Sieghart; Matthias Pinter Journal: Liver Cancer Date: 2018-06-22 Impact factor: 11.740
Authors: Quirino Lai; Alessandro Vitale; Tommaso M Manzia; Francesco G Foschi; Giovanni B Levi Sandri; Martina Gambato; Fabio Melandro; Francesco P Russo; Luca Miele; Luca Viganò; Patrizia Burra; Edoardo G Giannini Journal: Cancers (Basel) Date: 2019-10-15 Impact factor: 6.639
Authors: Jonathan Geograpo Navarro; Seok Jeong Yang; Incheon Kang; Gi Hong Choi; Dai Hoon Han; Kyung Sik Kim; Jin Sub Choi Journal: Ann Surg Treat Res Date: 2020-01-31 Impact factor: 1.859